U.S. markets open in 8 hours 46 minutes
  • S&P Futures

    4,558.75
    +21.25 (+0.47%)
     
  • Dow Futures

    34,791.00
    +225.00 (+0.65%)
     
  • Nasdaq Futures

    15,735.25
    +17.50 (+0.11%)
     
  • Russell 2000 Futures

    2,184.90
    +25.60 (+1.19%)
     
  • Crude Oil

    67.67
    +1.41 (+2.13%)
     
  • Gold

    1,783.20
    -0.70 (-0.04%)
     
  • Silver

    22.49
    +0.01 (+0.04%)
     
  • EUR/USD

    1.1291
    -0.0027 (-0.24%)
     
  • 10-Yr Bond

    1.3430
    -1.3430 (-100.00%)
     
  • Vix

    30.67
    -27.95 (-100.00%)
     
  • GBP/USD

    1.3232
    -0.0003 (-0.03%)
     
  • USD/JPY

    113.0360
    +0.2360 (+0.21%)
     
  • BTC-USD

    48,907.54
    -401.28 (-0.81%)
     
  • CMC Crypto 200

    1,257.85
    -183.91 (-12.76%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    27,937.12
    -92.45 (-0.33%)
     

MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of $1.7 billion.

  • The transaction is expected to close in the third quarter of 2021.

  • The purchase price of $34.00 per share in cash represents a premium of approximately 70% to Constellation's volume-weighted average price for the last five trading days.

  • Constellation is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics for cancer.

  • Constellation's two lead product candidates, pelabresib (CPI-0610), a BET inhibitor, and CPI-0209, a second-generation EZH2 inhibitor, are in mid-to late-stage clinical trials.

  • MorphoSys has also entered into a long-term strategic funding partnership with Royalty Pharma plc (NASDAQ: RPRX) for an upfront payment of $1.425 billion.

  • The proceeds will be used to support the financing of the Constellation transaction and the development of the combined pipeline.

  • Royalty Pharma will also provide MorphoSys with access to up to $350 million in Development Funding Bonds with the flexibility to draw over one year.

  • MorphoSys will receive additional payments of up to $150 million in milestone payments.

  • MorphoSys will host a conference call and webcast to discuss the transaction today at 8:00 a.m. ET.

  • Price Action: CNST shares are up 66.7% at $33.73, while MOR shares are down 14.4% at $18.91 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.